SMT201500203B - Proteina di fusione anticancro - Google Patents
Proteina di fusione anticancroInfo
- Publication number
- SMT201500203B SMT201500203B SM201500203T SM201500203T SMT201500203B SM T201500203 B SMT201500203 B SM T201500203B SM 201500203 T SM201500203 T SM 201500203T SM 201500203 T SM201500203 T SM 201500203T SM T201500203 B SMT201500203 B SM T201500203B
- Authority
- SM
- San Marino
- Prior art keywords
- fusion protein
- cancer fusion
- cancer
- protein
- fusion
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL393146A PL393146A1 (pl) | 2010-12-03 | 2010-12-03 | Przeciwnowotworowe białko fuzyjne |
| PL39459711 | 2011-04-18 | ||
| PCT/EP2011/071719 WO2012072815A1 (en) | 2010-12-03 | 2011-12-05 | Anticancer fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201500203B true SMT201500203B (it) | 2015-10-30 |
Family
ID=45065918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201500203T SMT201500203B (it) | 2010-12-03 | 2015-08-25 | Proteina di fusione anticancro |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9161991B2 (ru) |
| EP (1) | EP2646464B1 (ru) |
| JP (1) | JP5759557B2 (ru) |
| KR (1) | KR101952460B1 (ru) |
| CN (1) | CN103237808B (ru) |
| AU (1) | AU2011334868B2 (ru) |
| BR (1) | BR112013013548B8 (ru) |
| CA (1) | CA2814595C (ru) |
| CY (1) | CY1116646T1 (ru) |
| DK (1) | DK2646464T3 (ru) |
| EA (1) | EA024452B1 (ru) |
| ES (1) | ES2545895T3 (ru) |
| HK (1) | HK1186192A1 (ru) |
| HR (1) | HRP20150664T1 (ru) |
| HU (1) | HUE027068T2 (ru) |
| IL (1) | IL226207A (ru) |
| ME (1) | ME02224B (ru) |
| MX (1) | MX337436B (ru) |
| NZ (1) | NZ609216A (ru) |
| PL (1) | PL2646464T3 (ru) |
| PT (1) | PT2646464E (ru) |
| RS (1) | RS54057B1 (ru) |
| SG (2) | SG189370A1 (ru) |
| SI (1) | SI2646464T1 (ru) |
| SM (1) | SMT201500203B (ru) |
| WO (1) | WO2012072815A1 (ru) |
| ZA (1) | ZA201303449B (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL219845B1 (pl) * | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
| WO2014018113A1 (en) | 2012-07-24 | 2014-01-30 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| EP2890720B1 (en) | 2012-08-30 | 2019-07-17 | The General Hospital Corporation | Compositions and methods for treating cancer |
| WO2014057436A2 (en) | 2012-10-10 | 2014-04-17 | Adamed Sp. Z O.O. | Anticancer conjugate |
| WO2014141094A1 (en) | 2013-03-14 | 2014-09-18 | Adamed Sp. Z O.O. | Anticancer conjugate |
| US10428132B2 (en) | 2015-02-11 | 2019-10-01 | West China Hospital, Sichuan University | Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof |
| CN106632682A (zh) * | 2015-08-04 | 2017-05-10 | 清华大学 | 融合蛋白ifn-elp及其应用 |
| JP2022529943A (ja) | 2019-04-15 | 2022-06-27 | クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー | がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
| AU2021254283A1 (en) | 2020-04-10 | 2022-11-10 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| CA3211924A1 (en) | 2021-03-16 | 2022-09-22 | Sayantan Mitra | Masked activatable cytokine constructs and related compositions and methods |
| KR20230169700A (ko) | 2022-06-09 | 2023-12-18 | 제주대학교 산학협력단 | Trail을 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| ES2253753T3 (es) | 1995-06-29 | 2006-06-01 | Immunex Corporation | Citocina que induce apoptosis. |
| ATE275979T1 (de) * | 2000-06-09 | 2004-10-15 | Us Gov Health & Human Serv | Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugaten |
| DE60141992D1 (ru) * | 2000-09-05 | 2010-06-10 | Biosight Ltd | |
| DE10247755B4 (de) | 2002-10-14 | 2006-01-19 | Pfizenmaier, Klaus, Prof. Dr. | Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine |
| ATE501256T1 (de) | 2003-11-03 | 2011-03-15 | Beijing Sunbio Biotech Co Ltd | Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung |
| ZA200800974B (en) | 2005-08-16 | 2009-11-25 | Genentech Inc | Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues |
| WO2009002947A2 (en) | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
| ES2567704T3 (es) * | 2007-07-10 | 2016-04-26 | Apogenix Gmbh | Proteínas de fusión de colectina de la superfamilia de TNF |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| GB0723059D0 (en) | 2007-11-23 | 2008-01-02 | Nat Univ Ireland | Improved cytokine design |
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| WO2009086132A2 (en) | 2007-12-20 | 2009-07-09 | University Of Southern California | Design of spacers to increase the expression of recombinant fusion proteins |
| TW200950778A (en) | 2008-05-14 | 2009-12-16 | Genentech Inc | Methods of using Apo2L/TRAIL to treat cancer |
| LT2010012A (lt) | 2010-02-10 | 2011-08-25 | Uab Profarma, , | Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme |
-
2011
- 2011-12-05 CA CA2814595A patent/CA2814595C/en active Active
- 2011-12-05 EP EP11790636.2A patent/EP2646464B1/en active Active
- 2011-12-05 CN CN201180057053.1A patent/CN103237808B/zh active Active
- 2011-12-05 AU AU2011334868A patent/AU2011334868B2/en active Active
- 2011-12-05 JP JP2013541381A patent/JP5759557B2/ja active Active
- 2011-12-05 SG SG2013027479A patent/SG189370A1/en unknown
- 2011-12-05 US US13/989,969 patent/US9161991B2/en active Active
- 2011-12-05 DK DK11790636.2T patent/DK2646464T3/en active
- 2011-12-05 NZ NZ609216A patent/NZ609216A/en unknown
- 2011-12-05 BR BR112013013548A patent/BR112013013548B8/pt active IP Right Grant
- 2011-12-05 EA EA201390820A patent/EA024452B1/ru unknown
- 2011-12-05 SG SG10201509676UA patent/SG10201509676UA/en unknown
- 2011-12-05 RS RS20150407A patent/RS54057B1/en unknown
- 2011-12-05 MX MX2013006213A patent/MX337436B/es active IP Right Grant
- 2011-12-05 PT PT117906362T patent/PT2646464E/pt unknown
- 2011-12-05 KR KR1020137017194A patent/KR101952460B1/ko active IP Right Grant
- 2011-12-05 SI SI201130524T patent/SI2646464T1/sl unknown
- 2011-12-05 WO PCT/EP2011/071719 patent/WO2012072815A1/en active Application Filing
- 2011-12-05 PL PL11790636T patent/PL2646464T3/pl unknown
- 2011-12-05 ME MEP-2015-89A patent/ME02224B/me unknown
- 2011-12-05 HU HUE11790636A patent/HUE027068T2/en unknown
- 2011-12-05 ES ES11790636.2T patent/ES2545895T3/es active Active
-
2013
- 2013-05-07 IL IL226207A patent/IL226207A/en active IP Right Grant
- 2013-05-13 ZA ZA2013/03449A patent/ZA201303449B/en unknown
- 2013-12-06 HK HK13113599.3A patent/HK1186192A1/xx unknown
-
2015
- 2015-06-18 HR HRP20150664TT patent/HRP20150664T1/hr unknown
- 2015-08-25 SM SM201500203T patent/SMT201500203B/xx unknown
- 2015-08-25 CY CY20151100743T patent/CY1116646T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2019012I1 (lt) | Plazmos kalikreiną surišantys baltymai | |
| SMT201500203B (it) | Proteina di fusione anticancro | |
| BR112012030311A2 (pt) | anticorpo | |
| DK2536830T3 (da) | Polypeptider | |
| CR20130266A (es) | PROTEÍNAS DE UNIÓN AL TNF-a | |
| CO7020871A2 (es) | Anticuerpos anti-il-36r | |
| DK2443154T3 (da) | Bispecifikke antigenbindingsproteiner | |
| CO6900146A2 (es) | Imidazopiridazinas sustituidas con amino | |
| DK2728002T3 (da) | Heterodimeriseret polypeptid | |
| BR112015003838A2 (pt) | formulações de anticorpo e proteína | |
| IL232743A0 (en) | anticancer fusion protein | |
| CO6491031A2 (es) | Proteinas de fusion actriib-fc truncadas | |
| BR112013017629A2 (pt) | laminina-521 recombinante | |
| BR112014004902A2 (pt) | peptídeos | |
| CO6801637A2 (es) | Formulaciones de anticuerpos | |
| BR112013030352A2 (pt) | proteínas de ligação do receptor fc | |
| CO6791565A2 (es) | Anticuerpos anti-notch1 | |
| BR112013008347A2 (pt) | polipeptídeos de variantes cbh i | |
| SG10201500208SA (en) | Npp1 fusion proteins | |
| IL232834A0 (en) | anticancer fusion protein | |
| DK2721152T3 (da) | Dimere bindingsproteiner baseret på modificerede ubiquitiner | |
| EP2683742A4 (en) | NPP1 FUSION PROTEIN | |
| EP2698386A4 (en) | FUSION PROTEIN | |
| BR112014000262A2 (pt) | microviscosímetro capilar | |
| EP2657337A4 (en) | FUSION PROTEIN |